血站实验室新型冠状病毒相关检测平台的建立与安全防护  

Establishment and Safety Protection of SARS-CoV-2 Related Testing Platform in Pretransfusion Laboratories

作　　者：张立波[1] 戴宇东[1] 庞蓉蓉[1] 鲍晶晶[1] 李燕 叶盛[1] 仲昭衍 傅强[1] ZHANG Li-bo;DAI Yu-dong;PANG Rong-rong(Nanjing Red Cross Blood Center,Nanjing 210003)

机构地区：[1]南京红十字血液中心,210003 [2]山东烟台澳斯邦生物工程有限公司

出　　处：《临床输血与检验》2020年第3期246-249,共4页Journal of Clinical Transfusion and Laboratory Medicine

基　　金：南京市科技发展计划(医学项目)南京市医学科技发展重点项目(No.ZKX18050)资助。

摘　　要：目的 建立适合血站实验室的新冠病毒相关检测平台,同时避免生物安全风险发生。方法 通过对自动加样器程序的修改,调整液体曲线,降低注液速度,进行液面下加样及混匀;编辑酶免分析仪方法及LIS程序;修改核酸汇集程序等方法建立自动化的新型冠状病毒相关检测平台。结果 该平台可实现新型冠状病毒肺炎康复者恢复期血浆的IgM与IgG抗体检测、IgG抗体效价自动倍比稀释检测及新冠病毒核酸自动化检测。结论 所建立的新型冠状病毒相关检测平台可实现自动化、标准化的加样与检测,避免生物安全风险,为恢复期血浆的临床治疗提供有利的检测手段。Objective To establish a SARS-CoV-2 related detection platform suitable for pretransfusion laboratories to avoid biological risks.Methods An automated SARS-CoV-2 detection platform was established by modifying the automatic sampler program,adjusting the liquid curve,reducing the injection speed,performing sub-surface addition and mixing,editing the enzyme immunoassay and LIS program and optimizing the nucleic acid pooling program.Results The IgM and IgG antibody,IgG antibody with its titre,and nucleic acid of coronavirus in plasma from cured COVID-19 patients were successfully detected on the platform.Conclusion The established platform could realize automated and standardized sample addition and detection,and avoid biosafety risks.It may provide a favorable strategy for the recovery period plasma detection which could be helpful in COVID-19 treatment.

关 键 词：新型冠状病毒 自动化 酶免分析 核酸检测 

分 类 号：R446.6[医药卫生—诊断学] R563.1[医药卫生—临床医学]